EUVIMEDEUVIMED entdecken
Open Access

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status

Jun Zhang, Lanlan Zhou, Shuai Zhao, Wafik S El-Deiry

Oncotarget · 2024

DOI: 10.18632/oncotarget.28602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, 2024. Verfasst von Jun Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Hauptthemen laut MEDLINE: Trifluridine, Phenylurea Compounds, Pyridines, Drug Synergism. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrifluridinePhenylurea CompoundsPyridinesDrug SynergismProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Neovascularization, PathologicXenograft Model Antitumor AssaysNeoplastic Stem CellsGastrointestinal NeoplasmsUracilSTAT3 Transcription FactorThymineDrug CombinationsPyrrolidinesMutationHumansAnimalsMiceCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsMAP Kinase Signaling SystemSignal TransductionCell ProliferationAngiogenesis

Stichwörter der Autor:innen

ERK1/2TAS102angiogenesismicrovessel densityregorafenib

Substanzen

regorafenibTrifluridinePhenylurea CompoundsPyridinesProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)trifluridine tipiracil drug combinationUracilBRAF protein, humanSTAT3 Transcription Factor

Autor:innen und Institutionen

  • Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA.
  • Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA.
  • The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA.
  • Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA.
  • Hematology-Oncology Division, Department of Medicine, Lifespan Health System and Warren Alpert Medical School, Brown University, RI 02912, USA.

Zitieren

APA

Zhang, J., Zhou, L., Zhao, S., & El-Deiry, W. S. (2024). Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status. Oncotarget. https://doi.org/10.18632/oncotarget.28602

Vancouver

Zhang J, Zhou L, Zhao S, El-Deiry WS. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status. Oncotarget. 2024. doi:10.18632/oncotarget.28602

BibTeX
@article{Zhang2024,
  author = {Zhang, Jun and Zhou, Lanlan and Zhao, Shuai and El-Deiry, Wafik S},
  title = {Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28602}
}
Kostenlos starten →